Jasper Therapeutics Inc, also known as JSPR, is a rapidly advancing biopharmaceutical organization that focuses on the development and commercialization of groundbreaking treatments for hematological and other cancers. Established in Stanford University's laboratories, Jasper seeks to leverage its deep understanding of hematopoietic biology (which is the science of blood cell formation) to transform the field of bone marrow transplantations, and in extension, the cancer therapy space.
Ever since its inception, the company has been marked by relentless innovation and progress. Leading pharmaceutical minds spearhead Jasper's drive to confront the pervasive challenge of cancers and hematological disorders. Jasper's primary clinical solution is JSP191, an antibody designed for conditioning the hematopoietic stem cell grafts in both myeloablative and non-myeloablative settings. This solution targets the CD117 antigen, a protein found on the surface of hematopoietic stem and progenitor cells. By targeting this antigen, the compound effectively aids in the depletion of both healthy and diseased cells.
JSP191 is currently being evaluated in a Phase 1/2 clinical trial for patients with severe combined immunodeficiency (SCID) who are receiving a hematopoietic stem cell transplant. In addition, there is a Phase 1 clinical trial underway exploring the use of JSP191 for patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) in need of a transplant. JSP191 has been granted both Orphan Drug and Rare Pediatric Disease designations by the FDA for the treatment of SCID and Fanconi Anemia.
In terms of partnerships, Jasper Therapeutics Inc has arrangements with some prominent industry players. They have entered into an agreement with Takeda Pharmaceuticals and Gamida Cell, to explore a new regimen for stem cell transplantation. This collaborative deal marks Jasper's unwavering commitment to push scientific boundaries, optimize patient safety, and enhance clinical efficacy.
Jasper Therapeutics Inc is positioned at the cutting edge of its field, firmly founded in scientific excellence. This is a company endeavoring to make significant strides in the world of cancer treatment and beyond.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Jasper Therapeutics (NASDAQ: JSPR) is seeking stockholder approval to increase its authorized common stock from 490 million to 675 million shares. This move is necessary to satisfy the Merger Agreement requirements following its acquisition of Kira Pharmaceuticals. Stockholders will vote on this proposal, along with a potential reverse stock split, at a virtual special meeting on September 30, 2026.
Jasper Therapeutics Inc. reported better-than-expected second-quarter fiscal 2026 results, with an adjusted loss per share of $0.10 against an estimated loss of $0.28. Despite this beat, the company's stock fell 4.24% in pre-market trading. The company also highlighted its recent acquisition of Kira Pharmaceuticals and a $132 million financing round, which is expected to fund operations through the second half of 2028.